Resources

Selected
  • Systematic reviews (SYSVAC)
Type of publications
Regions
Diseases
Vaccine topics
Target population
Publication date
3034 results found
2025 ∙ Reiter, L. Voracek, M. Betsch, C. Bohm, R.
Emphasising herd immunity in vaccine advocacy: a systematic review and meta-analysis
All age groups Parents/caregivers Healthcare workers Acceptance Coverage
Methodological quality (AMSTAR 2):
Not applicable
2025 ∙ Wang, Y. Zhang, Y. Wang, J. Shi, N. Jin, H.
Enhancing influenza vaccination uptake: a systematic review and meta-analysis of intervention strategies
All age groups Pregnant women Healthcare workers Influenza Coverage
Methodological quality (AMSTAR 2):
Not applicable
2025 ∙ Wu, P. C. Huang, I. H. Wang, C. W. Chung, W. H. Chen, C. B.
Erythema Multiforme and Epidermal Necrolysis Following COVID-19 Vaccines: A Systematic Review
All age groups COVID-19 Safety Administration
Methodological quality (AMSTAR 2):
Critically low
2025 ∙ Pan, Y. Jia, Z. Zhang, Y. Wu, Y. Jiang, J.
Estimates of the global prevalence of occult hepatitis B virus infection in population under 18 years old: a systematic review and meta-analysis
Newborn Children Adolescents Hepatitis B Efficacy/effectiveness Administration
Methodological quality (AMSTAR 2):
Critically low
2025 ∙ Liu, J. Zhang, Y. Zhang, H. Tan, H.
Estimating the effects of interventions on increasing vaccination: systematic review and meta-analysis
All age groups Coverage
Methodological quality (AMSTAR 2):
Not applicable
2025 ∙ Szondy, I. Lorincz, K. Walter, A. Mohammed, A. A. Hegyi, P. Kiss, N. Meznerics, F. A. Banvolgyi, A.
Evaluating cross-protection: Meningococcal vaccines show effectiveness in gonorrhoea prevention - A systematic review and meta-analysis
All age groups Meningococcal disease Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2025 ∙ Jotautis, V. Sarantaki, A.
Evaluating the Efficacy and Safety of Hepatitis E Vaccination in Reproductive-Age Women: A Systematic Review and Meta-Analysis
Adolescents Adults Hepatitis E Efficacy/effectiveness Safety
Methodological quality (AMSTAR 2):
Critically low
2025 ∙ Alandijany, T. A. Qashqari, F. S.
Evaluating the efficacy, safety, and immunogenicity of FDA-approved RSV vaccines: a systematic review of Arexvy, Abrysvo, and mResvia
All age groups Pregnant women RSV (Respiratory syncytial virus) Efficacy/effectiveness Safety Administration
Methodological quality (AMSTAR 2):
Low
2025 ∙ Siddiqui, E. Khan, M. S. Khalid, M. Chandani, H. K. Naeem, U. Khan, M. M. Wasti, S. O.
Evaluating the immunogenicity and safety of ID93 + GLA-SE in BCG-vaccinated healthy adults: a systematic review and meta-analysis of randomized controlled trials
Adults Tuberculosis Efficacy/effectiveness Safety
Methodological quality (AMSTAR 2):
Critically low
2025 ∙ Williams, L. R. Hombach, J. Marti, M.
Evaluating the Immunogenicity, Efficacy, and Effectiveness of Recombinant Zoster Vaccine for Global Public Health Policy
All age groups Herpes zoster Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
Loading...